BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
BriaCell報告稱，在接受Briacell的Bria-IMT方案治療的可評估的2期晚期乳腺癌患者中，初期疾病控制率爲61％；在先前ADC治療失敗的可評估患者中，報告的控制率爲50％
- Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study
-
Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
- Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor "no longer observed" following BriaCell treatment
- 在BriaCell的關鍵性3期研究中，在使用相同配方治療的可評估的2期患者中觀察到的疾病控制率爲61％
-
接受3期製劑治療但先前抗體藥物偶聯物（ADC）治療失敗的可評估患者的疾病控制率爲50％
- 在BriaCell治療後 “不再觀察到” 轉移性肝腫瘤的先前4種療法，包括ADC療法，該療法的受試者均失敗
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。